Clinical Trials Sponsored by Getz Pharma

Total 8448 results

AM-Pharma

Withdrawn

A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis (LIST)

Bacteremia | Staphylococcal Infections

Netherlands
Vifor Pharma

Completed

Study of Phosphate Levels in Patients With Chronic Kidney Disease (PA21)

Chronic Kidney Disease

United States, Switzerland, Romania, Croatia, Bulgaria, Germany, Czech Republic, Poland, Russian Federation
UCB Pharma

Completed

Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA) (MARVELOUS)

Rheumatoid Arthritis

Denmark, Netherlands, Poland, Sweden
LEO Pharma

Completed

Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)

Scalp Psoriasis

Germany
UCB Pharma

Completed

Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

Japan
UCB Pharma

Completed

POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis)

Seasonal Allergic Rhinitis
UCB Pharma

Completed

Compare the Efficacy of Levocetirizine to Montelukast in Reducing Symptoms of SAR in Sensitive Subjects Exposed to Ragweed Pollen

Rhinitis, Allergic, Seasonal

Canada
UCB Pharma

Completed

Efficacy and Safety of Levocetirizine for Treatment of Recurrent Cough Associated With Other Allergic Symptoms in Children

Cough
UCB Pharma

Completed

Double-blind, Placebo-controlled Study of Levetiracetam in Adults With POS

Epilepsy, Partial
UCB Pharma

Completed

Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy

Epilepsy, Partial
UCB Pharma

Completed

A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN)

Neuralgia, Postherpetic
LEO Pharma

Completed

The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847

Renal Impairment

Canada
LEO Pharma

Completed

LEO 22811 - Single Dose Bioavailability Study of Tablet Versus Oral Solution in Healthy Subjects

Healthy

United Kingdom
LEO Pharma

Completed

Assessment of the Phototoxic Potential of LEO 29102 Cream

Atopic Dermatitis

France
LEO Pharma

Completed

A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis

Atopic Dermatitis

Netherlands
Clavis Pharma

Completed

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

AML | Hematologic Malignancies

United States, United Kingdom, France, Germany, Italy, Norway
UCB Pharma

Completed

Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + Adults

Generalized Convulsive Epilepsy
Clavis Pharma

Completed

A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer

Ovarian Cancer

Belgium, Italy
Clavis Pharma

Completed

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

Malignant Melanoma

United States, Sweden, Norway
UCB Pharma

Completed

Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis

Arthritis, Rheumatoid
Clavis Pharma

Completed

Elacytarabine Mass Balance Study in Healthy Volunteers

Not Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy Subjects

United Kingdom
Advanz Pharma

Withdrawn

A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)

Atrial Fibrillation
UCB Pharma

Completed

Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older

Seizures

Belgium
Kiadis Pharma

Completed

Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Hematologic Diseases | Hematologic Malignancies

Canada
HRA Pharma

Completed

Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.

Emergency Contraception

Sweden, Netherlands, United Kingdom
LEO Pharma

Terminated

Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.

Atopic Dermatitis

Germany
Psyadon Pharma

Completed

Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan Disease

Lesch-Nyhan Disease

United States
LEO Pharma

Terminated

Cromoglicate in Mastocytosis

Mastocytosis

Germany
UCB Pharma

Completed

Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures

Epilepsy, Partial

United States, France, United Kingdom, Germany, Belgium, Mexico, Poland, India, Romania, South Africa, Canada, Brazil, Russian Federation, Czech Republic, Hungary, Italy
UCB Pharma

Completed

Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

Immune System Diseases | Autoimmune Diseases | Lupus Erythematosus, Systemic | Skin and Connective Tissue Diseases | Connective Tissue Disease

Belgium, Bulgaria, Germany
UCB Pharma

Completed

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine Transdermal Patch in Healthy Chinese Subjects

Healthy

China
UCB Pharma

Completed

Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding

Peptic Ulcer

France, Poland, Spain, Belgium, Greece, Hungary
UCB Pharma

Completed

A Multicenter, Open-label Study to Determine the Effects of Lacosamide on Sleep in Healthy Subjects

Healthy Subjects

United States
UCB Pharma

Completed

An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in Chinese

Human Volunteers

China
UCB Pharma

Completed

Study of Epratuzumab in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States
UCB Pharma

Completed

Human Pharmacology Study (Keppra Dry Syrup Bioequivalence Study)

Healthy

United Kingdom
UCB Pharma

Terminated

Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)

Lupus Erythematosus, Systemic

United States
UCB Pharma

Terminated

Study of Epratuzumab in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States, Belgium, Netherlands, United Kingdom, Spain, Hungary
UCB Pharma

Completed

Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema

Dermatitis | Eczema

Korea, Republic of
UCB Pharma

Completed

CUTE (Chronic Urticaria Treatment Evaluation)

Chronic Idiopathic Urticaria

France, Germany, United Kingdom, Belgium, Spain, Malaysia, Romania, South Africa, Italy
UCB Pharma

Completed

Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations

Parkinson's Disease

Germany, Austria, United Kingdom
Otic Pharma

Completed

Safety and Efficacy of Once-Daily Dosing of FoamOtic Cipro Compared to Twice-Daily Dosing of Ciloxan Ear Drops in Patients With Acute External Otitis (Once-a-day)

Otorhinolaryngologic Diseases | Ear Diseases | Otitis Externa | Otitis

Israel
Clavis Pharma

Completed

A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour

Solid Tumors

Netherlands, Belgium
UCB Pharma

Completed

Effect of Brivaracetam in Photosensitive Epileptic Subjects

Epilepsy

France, Germany
Clavis Pharma

Completed

A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer

Colorectal Cancer | Advanced Colorectal Cancer

United Kingdom
Axcan Pharma

Completed

Pilot Study of Ursodesoxycholic Acid in Non-Alcoholic Steatohepatitis (URSONASH)

Serum Levels of ALAT Transaminases | Serum Markers for Fibrosis and Hepatic Inflammation

France
Advanz Pharma

Completed

Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence

Atrial Fibrillation

Netherlands, United States, Canada, Denmark
AM-Pharma

Completed

Safety of a Single Dose of 5 mg of hLF1-11 Given to Autologous Haematopoietic Stem Cell Transplant Recipients

Bacterial Infections and Mycoses | Hematopoietic Stem Cell Transplantation

Netherlands
Dafra Pharma

Completed

Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria

Plasmodium Falciparum Malaria

Cameroon, Mali, Rwanda, Sudan
UCB Pharma

Completed

Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA)

Epilepsy

Spain

3

Subscribe